Invictus Oncology gets $2m from Navam, Aarin
Indian investors Navam Capital and Aarin Capital have invested INR10.5 million ($1.88 million) in Delhi-based Invictus Oncology as part of a Series A round of funding.
Invictus is working on the development of new chemotherapy models that will be less toxic than the treatment now available. A similar range of anti-cancer drugs would cost $9,000 per dose in the US.
The funding will be used to advance treatment of different types of cancers.
Invictus is one of three startups founded by Shiladitya Sengupta, an assistant professor of medicine at Harvard Medical School. He also started Vyome Biosciences in 2010 to develop anti-dandruff products and anti-acne products, along with treatments for pigmentation disorders.
Navam and Aarin have also backed Vyome, which raised $3.3 million in Series A financing in September 2012 from the the two investors as well as IndoUS Venture Partners.
Vyome raised $1 million in seed funding from Navam in November 2010.
More on South Asia
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.